Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Obinutuzumab [USAN:INN]
RN: 949142-50-1
UNII: O43472U9X8


  • Anti-CD20 mAb for treating B-cell lymphoid cancers.
  • Anti-CD20 mAb for treating B-cell lymphoid cancers.

    NCI: A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells. (NCI Thesaurus)

Molecular Formula

  • Unspecified

Classification Codes

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Treatment of Lymphoma, Oncology

Names and Synonyms

Name of Substance

  • Afutuzumab
  • Obinutuzumab [USAN:INN]


  • Afutuzumab
  • Afutuzumab [Previous USAN]
  • GA 101
  • GA-101
  • GA101
  • GA101 antibody
  • Gazyva
  • Gazyvaro
  • HSDB 8249
  • huMAB(CD20)
  • huMAB
  • huMABCD20
  • Obinutuzumab
  • R 7159
  • R-7159
  • R7159 cpd
  • Ro 5072759
  • RO-5072759
  • Ro5072759
  • UNII-O43472U9X8

Registry Numbers

CAS Registry Number

  • 949142-50-1


  • O43472U9X8

System Generated Number

  • 0949142501